Recital 7, Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012…

In forcecited 1×

A distinction should be drawn between existing active substances which were on the market in biocidal products on the transposition date set in Directive 98/8/EC and new active substances which were not yet on the market in biocidal products on that date. During the ongoing review of existing active substances, Member States should continue to allow biocidal products containing such substances to be made available on the market according to their national rules until a decision is taken on approval of those active substances. Following such a decision Member States, or, where appropriate, the Commission, should grant, cancel or modify authorisations as appropriate. New active substances should be reviewed before biocidal products containing them are placed on the market, so as to ensure that new products that are placed on the market comply with the requirements of this Regulation. However, to encourage the development of new active substances, the evaluation procedure for new active substances should not prevent Member States or the Commission from authorising, for a limited period of time, biocidal products containing an active substance before it is approved, provided that a full dossier has been submitted and it is believed that the active substance and the biocidal product satisfy the conditions set out in this Regulation.

  • Judgment of the General Court (Ninth Chamber) of 17 January 2024. Troy Chemical Company BV and Troy Corp. v European Commission.Decision

    Finally, it should be recalled that the objective of the transitional period of access to national markets from which certain biocidal products benefited, first under Article 16 of Directive 98/8 and then under Article 89 of Regulation No …

    17 Jan 2024 · 62021TJ0297